Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling

Angela Effinger; Caitriona O'Driscoll; Mark McAllister; Nikoletta Fotaki

Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling

Angela Effinger
, Caitriona O'Driscoll
, Mark McAllister
, Nikoletta Fotaki

School of Pharmacy

Pfizer
University of Bath, Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English (Ireland)
Journal	European Journal of Pharmaceutical Sciences
Volume	157
Publication status	Published - 2021

Cite this

@article{14341b4cd3f64b0e90ca8b95bffa710f,

title = "Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling",

author = "Angela Effinger and Caitriona O'Driscoll and Mark McAllister and Nikoletta Fotaki",

year = "2021",

language = "English (Ireland)",

volume = "157",

journal = "European Journal of Pharmaceutical Sciences",

issn = "0928-0987",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling

AU - Effinger, Angela

AU - O'Driscoll, Caitriona

AU - McAllister, Mark

AU - Fotaki, Nikoletta

PY - 2021

Y1 - 2021

M3 - Article

SN - 0928-0987

VL - 157

JO - European Journal of Pharmaceutical Sciences

JF - European Journal of Pharmaceutical Sciences

ER -